Month: May 2024

Kartoon Channel!’s Streaming Business Achieved Profitability in the First Quarter of 2024 and Continues Growth; User Rankings in Apple App Store Now Beat Disney+; Operational Efficiencies Expected to Drive Company-Wide Profitability Direct Operating Costs Reduced by Over 60% in the First Quarter of 2024 Compared to Same Period in 2023; 29% Reduction Sequentially Compared to the Fourth Quarter of 2023 Flagship Brand, “Stan Lee Universe,” Grows Across Multiple Sectors: New Store on Amazon; New Partnership with World’s Largest Digital Collectibles Platform, “VeVe” for Collectibles; and New YouTube Channel, ‘Stan Lee Presents,’ Debuts with Over 300,000 Subscribers, Driving Revenues and Enhancing Global Fan Engagement, with Marvel Mastermind Company Launches New AI Initiative Using Nvidia Omniverse, Revolutionizing Animation...

Q1’24 revenue of $5.3M is up 340% vs. Q1’23 and at the midpoint of Lifeward’s guidance range Newly established Medicare payment for ReWalk Personal Exoskeleton favorably impacts Q1’24 results Medicare Administrative Contractors (“MACs”) approve 14 claims since fee schedule established MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2024 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced its financial results for the three months ended March 31, 2024. Recent Highlights and Milestones for LifewardThe Centers for Medicare & Medicaid Services...

Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “This quarter we remained laser-focused on progressing the NAVIGATE Phase 2b/3 trial of belapectin, which has a Fast Track Designation from the U.S. Food & Drug...

Strong First Quarter 2024 Net Revenues of $10.6 Million Support Fiscal Year 2024 Triple-Digit Revenue Growth & Positive Cash Flow Objectives First Quarter 2024 Net Revenues of $10.6 Million Represent 84.5% of the Company’s Full Year Revenue in 2023 Awarded Second Contract by DOJ Agency for $2.35 Million for Company’s Outpost AI Appliance to Support Emerging Public Safety and Investigative Requirements REDMOND, Wa., May 15, 2024 (GLOBE NEWSWIRE) — Airship AI Holdings, Inc. (NASDAQ: AISP) (“Airship AI” or the “Company”), a leader in AI-driven video, sensor, and data management surveillance solutions, today reported its financial and operational results for the first quarter ended March 31, 2024. Q1 2024 Financial HighlightsNet revenues for the quarter ended March 31, 2024 were $10.6 million. Gross profits for the quarter ended...

Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global Intellectual Property Surrounding Versamune® Platform PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a business update and reported financial results for the first quarter of 2024. The press release will be available in the Investor Relations section of the Company’s website at www.pdsbiotech.com. Recent DevelopmentsHosted a Key Opinion Leader event on May 8, 2024, during which prominent experts...

– CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024- – Completed up to $149.4 million private placement with leading healthcare investors in early 2Q 2024 – BOSTON, May 15, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the first quarter ended March 31, 2024. “Building on a year of high operational and clinical achievement, already in 2024, we have strengthened our financial resources and published data that further positions our lead clinical program, neflamapimod, as a highly differentiated, potential first-to-market treatment...

Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place in Milan, Italy from June 5-8, 2024 End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) expected in the second quarter of 2024 Preparations are underway to start a pivotal Phase 3 trial evaluating denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $193.7 million as of March 31, 2024 SAN MATEO, Calif., May 15, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional...

Achieved a 1,407% revenue increase to $1.47 million in Q1 2024. Increased gross margin to 19% in Q1 2024, up from -3% last year. Secured $8 million in recurring revenue plus $1.1 million in rotational retailer commitments.BEND, Ore., May 15, 2024 (GLOBE NEWSWIRE) — BranchOut Food Inc. (NASDAQ: BOF), a leading food technology company specializing in dehydrated fruit and vegetable-based products, today announced its recent accomplishments and financial results for the first quarter ended March 31, 2024. The Company reported a 1,407% increase in revenue for the first quarter ending March 31, 2024 of $1.47 million compared to $97,000 in the year ago quarter. Additionally, BranchOut Food achieved a gross margin of 19% in Q1 2024, a significant improvement from -3% in Q1 2023. Eric Healy, CEO of BranchOut Food, commented, “This quarter’s...

Consolidated Revenues of $68.7 million, up 7% from Last Year U.S. and Canada Revenues up 22% from Last Year Consolidated Operating Income of $9.6 million compared to $3.2 million Last Year Diluted EPS of $0.28 compared to $0.04 Last YearAUBURN HILLS, Mich., May 15, 2024 (GLOBE NEWSWIRE) — SPAR Group, Inc. (NASDAQ: SGRP) (“SPAR,” “SPAR Group” or the “Company”), today announced first-quarter 2024 consolidated revenues of $68.7 million, a 6.7% increase from the first quarter of 2023. Consolidated operating income was $9.6 million, up 204% compared to the first quarter of 2023. Diluted earnings per share were $0.28, including one-time recognition of a $7.2 million pre-tax gain on sale for the quarter, up 600% from the same period in 2023. “I want to thank all of our team for their hard work and efforts,” said Mike Matacunas, SPAR...

Reported Gross Profit of Approximately $0.22 Million for Third Quarter Fiscal 2024, up 47% Year-Over-Year Secured a USD$2 million marketing contract aimed to promote prestigious Korean beauty products using its advanced AI Marketing Engine, strategically leveraging the vast revenue potential of the Malaysian and Southeast Asia beauty market Emerged as Exclusive Partner for AI Blockchain Wallet on Telegram, Paving the Way for New Business Opportunities and Spearheading Innovation in the Blockchain Industry Won the silver trophy for Best eCommerce Solution of the MARKETING-INTERACTIVE Asia eCommerce Awards 2023 Successfully Regained Compliance with Nasdaq Minimum Bid Price Requirement. NEW YORK and KUALA LUMPUR, Malaysia, May 15, 2024 (GLOBE NEWSWIRE) — Treasure Global Inc (NASDAQ: TGL) (“TGL,” “Treasure Global” or the “Company”),...